STANDARD TREATMENT WITH BEVACIZUMAB AS TARGETED THERAPY IN CERVICAL CANCER

被引：0

作者：

Enriquez-Aceves, Isabel ^{[1
]}

Galicia-Carmona, Tatiana ^{[2
,3
]}

Coronel-Martinez, Jaime A. ^{[2
,3
]}

Espinosa-Romero, Raquel ^{[3
]}

Calderillo-Ruiz, German ^{[3
]}

Cortes-Esteban, Patricia ^{[4
]}

Cetina-Perez, Lucely ^{[2
,3
]}

机构：

[1] Hosp Inst Seguridad & Serv Sociales Trabajadores, Dept Med Oncol, Leon, Gto, Mexico

[2] Inst Nacl Cancerol, Dept Clin Res, Mexico City, DF, Mexico

[3] Inst Nacl Cancerol, Dept Med Oncol, Mexico City, DF, Mexico

[4] Ctr Med Nacl 20 Noviembre, Dept Med Oncol, Mexico City, DF, Mexico

来源：

REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION | 2020年 / 72卷 / 04期

关键词：

Bevacizumab; Cervical; Cancer; Metastatic antiangiogenic; PHASE-II TRIAL; SQUAMOUS-CELL-CARCINOMA; COMBINATION THERAPY; 3RD-LINE TREATMENT; OPEN-LABEL; RECURRENT; PERSISTENT; CHEMOTHERAPY; CARBOPLATIN; PACLITAXEL;

D O I：

10.24875/RIC.20000061

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Metastatic, recurrent, or persistent disease in cervical cancer has a poor prognosis. Historically, this group of patients has had limited treatment options, even with the best cytotoxic treatments (platinum-based chemotherapy [CT] doublets). Therefore, investigating new medications that help improve the patient's quality of life and survival has been essential. Angiogenesis has been shown to play a critical role in tumor cell growth and survival. Bevacizumab is a recombinant humanized monoclonal G1 immunoglobulin targeted against vascular endothelial growth factor. The combination of CT and bevacizumab is associated with an increase in overall survival as well as in progression-free survival and response rates.

引用

页码：213 / 218

页数：6

共 50 条

[41] Targeted therapy of colorectal cancer: Clinical experience with bevacizumab
Fernando, NH
Hurwitz, HI
ONCOLOGIST, 2004, 9 : 11 - 18
[42] Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized Therapy
Cohen, Alexander C.
Roane, Brandon M.
Leath, Charles A., III
DRUGS, 2020, 80 (03) : 217 - 227
[43] The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis
Liu, Shiru
Kasherman, Lawrence
Fazelzad, Rouhi
Wang, Lisa
Bouchard-Fortier, Genevieve
Lheureux, Stephanie
Krzyzanowska, Monika K.
GYNECOLOGIC ONCOLOGY, 2021, 161 (02) : 601 - 612
[44] Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer
Eskander, Ramez N.
Tewari, Krishnansu S.
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2014, 25 (03) : 249 - 259
[45] Treatment strategies in cervical cancer: treatment of advanced disease
Valdivia, Augusto
Grau-Bejar, Juan Francisco
Garcia-Duran, Carmen
Oaknin, Ana
JOURNAL OF CANCER METASTASIS AND TREATMENT, 2022, 8
[46] Impact of Bevacizumab-containing Primary Treatment on Outcome of Recurrent Ovarian Cancer: An Italian Study
Gadducci, Angiolo
Cosio, Stefania
Lissoni, Andrea Alberto
Zizioli, Valentina
Adorni, Marco
Ferrero, Anna Maria
Landoni, Fabio
Sartori, Enrico
ANTICANCER RESEARCH, 2020, 40 (03) : 1543 - 1550
[47] Molecular targeted therapy for the treatment of gastric cancer
Xu, Wenting
Yang, Zhen
Lu, Nonghua
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2016, 35
[48] The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer
Zhang, Wenwen
Shen, Zhaojun
Luo, Hui
Hu, Xiaoli
Zheng, Lihong
Zhu, Xueqiong
CURRENT DRUG TARGETS, 2017, 18 (10) : 1125 - 1131
[49] The effect of bevacizumab maintenance therapy on survival in recurrent epithelial ovarian cancer
Bakir, Mehmet Sait
Birge, Ozer
Karadag, Ceyda
Dogan, Selen
Tuncer, Hasan Aykut
Simsek, Tayup
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2021, 42 (06) : 1198 - 1204
[50] Prospects of Molecularly-Targeted Therapies for Cervical Cancer Treatment
de Freitas, Antonio Carlos
Gomes Leitao, Maria da Conceicao
Coimbra, Eliane Campos
CURRENT DRUG TARGETS, 2015, 16 (01) : 77 - 91

← 1 2 3 4 5 →